HIV & AIDS Research Challenges in Sub-Saharan Africa

Geoffrey Setswe MPH, DrPH

Presentation at Winter School 2008 University of Limpopo, School of Public Health



HIV and AIDS research consists of:

- Basic and clinical research to understand and treat HIV infection and its related conditions;
- Social and behavioural research to track and prevent the spread of HIV, understand the behaviours that put people at risk for HIV infection, and develop interventions to change these behaviours;
- Health services and policy research to address the nexus between scientific research and the application of that research into health care services.



Social Aspects of HIV/AIDS and Health

Milestones in HIV and AIDS research

- 1. Identification of the human immunodeficiency virus (HIV),
- 2. Development of drugs to treat HIV infection,
- **3.** Advances in the treatment and prevention of several HIV-related diseases and infections,
- 4. Identification of barriers to access to prevention of HIV,
- 5. The discovery that the use of antiretroviral drugs can dramatically reduce the risk of transmission of HIV from a pregnant woman to a foetus and
- 6. A reduction in the number of new HIV infections in some countries

Source: Sorian and Kates, 2002 a difference



Identification of the human immunodeficiency virus (HIV)

 Luc Montagnier of the Pasteur Institute and Robert Gallo of the National Cancer Institute isolated the human immunodeficiency virus (HIV), the viral agent causing AIDS as early as 1984.



Development of drugs to treat HIV infection

- The first antiretroviral drug, Zidovudine or AZT (a nucleoside analogue) was approved by US FDA in 1987;
- AZT was approved for paediatric use in 1990.
- US FDA approved the first Protease Inhibitor, Saquinavir, in a record time in 1995, ushering in a new era of highly active antiretroviral therapy (HAART);
- The first Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Nevirapine, was approved for use in 1996.
- In 2003, the SA Government announced a comprehensive antiretroviral treatment programme to treat HIV/AIDS.



Advances in the treatment and prevention of HIV-related diseases

- The first guidelines for the prevention of Pneumocystis Carinii Pneumonia (PCP), a major cause of morbidity and mortality for people with HIV, were issued by the Centres for Disease Control (CDC) in 1989;
- The first guidelines for the prevention of opportunistic infections in persons infected with HIV were issued in 1995.
- Advances in the treatment of CMV retinitis, and toxoplasmosis.
- Scientists at Harvard Medical School discovered a gene that blocks the transmission of HIV in old world monkeys*.

Sources: Sorian and Kates, (2002) and erence *Stremlau, Owens, Perron et al., (2004)



Identification of barriers to access to prevention of HIV

- U.S FDA approved the female condom for sale in 1993;
- The development of a test to detect the presence of antibodies to HIV in blood and other tissues. The FDA licensed this test in 1985;
- In 1996, the FDA approved an HIV urine test and first HIV home testing and collection kit. In the same year, a viral load test, a test that measures the level of HIV in the body, was also approved.
- The first large scale human trials or phase III trials for an HIV vaccine began in 1998.
- OraQuick, a rapid HIV-1 antibody test, was approved as the first rapid test to use finger prick in 2002

Social science that makes a difference Source: Sorian and Kates, (2002).



PMTCT

- In 1994, the U.S. Public Health Service recommended the use of AZT by pregnant women to reduce perinatal transmission of HIV, based on "076" study showing up to 70% reduction in transmission;
- Dual therapy for PMTCT



A reduction in the number of new HIV infections in some countries

- HSRC (2005) study indicated that there was a reduction in the number of new HIV infections in South Africa due to successful community and individual level prevention interventions.
- Dramatic reductions in HIV prevalence have also been reported in:
 - Uganda (from 25% in 1990's to 6% in 2003)
 - Kenya (from 9.4% in late 1990's to 6.7% in 2004).

Source: (Shisana and Simbayi, 2003)difference



Impact of AIDS research on other areas of medical science

- The development of flu drug, Relenza directly benefited from AIDS research.
- The drug known as 3TC, developed to treat AIDS, is now the most effective therapy for chronic hepatitis B infection.
- Drugs developed to prevent and treat AIDS-related opportunistic infections also provide benefit to patients undergoing cancer chemotherapy or receiving anti-transplant rejection therapy.
- AIDS is also providing new understanding of the relationship between viruses and cancer.



Other impacts of HIV research

- Accelerated research into viruses and retroviruses;
- Provided insight into treatment with PI of other conditions including bone loss and heart muscle damage;
- Enhanced understanding of the spread of infectious agents through the blood/brain barrier (which has implications for research on Alzheimer's disease, dementia, encephalitis, and meningitis);
- Improved treatment and prevention of infections among people with advanced breast cancer, organ transplants, or autoimmune conditions;
- Improved diagnostic tests to detect cancer cells and TB.

Social science that makes a difference Source: Sorian and Kates, (2002)





1. More accurate estimation of the HIV and AIDS epidemic

- What is the prevalence of HIV in South Africa? Do we have an accurate estimation of the HIV prevalence?
- What about the incidence of HIV?
- Antenatanal sero-prevalence surveys vs. Population-based surveys



2. Health disparities and the impact of HIV on women and young people

- Despite recent positive trends, HIV remains a leading cause of death among the poor, women and young people.
- Research challenges include increasing the number of Black researchers conducting behavioural and clinical research.
- Developing and evaluating prevention interventions designed to reduce HIV risk behaviors and transmission in communities disproportionately impacted by HIV;
- Reducing barriers to prevention and treatment.





3. Development of simpler, less toxic medications

Clinical studies are needed to:

- identify strategies for the long-term use of HIV antiretroviral therapy (ART);
- answer questions such as when to begin therapy, how to manage side effects; how to improve adherence to HIV therapy;
- avoid the development of drug resistance;
- how to treat patients for whom therapy is failing.

Researchers should focus on the development of new, simpler, less toxic, and less expensive drugs to deal with side effects and complicated regimens.



4. Focus on behavioural and social science research

Behavioural and social science research investigates ways to understand and change behaviours such as:

- The tendency to have multiple partners
- Having unprotected sex
- Having concurrent partners
- Lack of self-efficacy skills
- Failure to disclose one's sero-status to a partner
- Sharing unsterile needles with other drug users
- Delaying age of sexual intercourse

It also looks at factors that may lead to behaviours like low self-esteem, poverty and complacency.

Social science that makes a difference



Weapons of mass protection!





Social Aspects of HIV/AIDS and Health

5. Research on prevention technologies

- How far are we from getting an HIV vaccine?
- What progress are we making in obtaining a user-friendly microbicide?
- How accessible, affordable and user-friendly are femidoms?
- How extensive are male condoms used?
- New evidence about the efficacy of male circumcision in HIV prevention?



5

6. Translating research into policy and practice

Assumption:

• We conduct good quality research to provide evidence of effective interventions. Research is published by high-level peer-reviewed journals.

• The evidence is used to develop good policies.

• Policies are then implemented as best practice interventions and then we "defeat" the HIV epidemic.



The AIDS epidemic has taught us to be innovative and to invent new ways of doing things. We think we have evidence of HIV prevention strategies that work!



Picture source: Naidoo D (2007). Science, Technological and Involution A Strategic Imperative for South Africa



However, despite our innovation, inventiveness and compelling evidence of effective strategies, the "killer virus" is still chasing and killing us!



Picture source: Naidoo D (2007). Science, Technological and Innovation Sciences A Strategic Imperative for South Africa